-
-
-
-
-
-
-
Qiagen launches new bloodstream infection panel in Europe
-
-
-
-
-
-
-
QIAGEN launches QIA Agent, connecting AI-driven scientific guidance across Sample to Insight workflows
-
-
-
-
-
-
-
QIAGEN lowers 2026 outlook as QuantiFERON immigration testing drops
-
-
-
-
-
-
-
Parse Biosciences Launches Evercode Whole Transcriptome V4 With Shorter Workflow, Higher Sensitivity and Higher Cell Recovery
-
-
-
-
-
-
-
QIAGEN Announces Details for Completion of Synthetic Share Repurchase of up to Approximately $500 Million
-
-
-
-
-
-
-
QIAGEN delivers solid Q1 2025 results exceeding outlook; will seek shareholder approval to initiate a dividend and new $500 mn repurchase
-
-
-
-
-
-
-
QIAGEN announces preliminary Q2 2021 results exceeding outlook, updates full-year 2021 outlook for declining COVID-19 test trends and plans new $100 million share repurchase program
-
102,067 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

